PFIZER ONCOLOGY PRESS KIT
PLEASE NOTE: All assets on this page are intended for use by U.S. media professionals only.
Over the past decade Pfizer Oncology has taken bold new approaches to translate scientific research into effective medicines for people living with cancer. We are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 23 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma.
For the latest information on our growing pipeline, product portfolio and collaborations with the broader cancer community, visit this page periodically for updates.
PFIZER AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) VIRTUAL CONGRESS 2020
Pfizer will present data across its industry-leading oncology portfolio, covering multiple tumor types and mechanisms of action. This year, we highlight more than 50 abstracts representing data from nine approved and investigational Pfizer medicines, including several biomarker-driven and immuno-therapies.
PFIZER ABSTRACT PLAIN LANGUAGE SUMMARIES (APLS) AT THE ESMO VIRTUAL CONGRESS 2020
To help interested non-scientists better understand the latest research, we are developing summaries in plain language for Pfizer research results presented at medical conferences. We call these “abstract plain language summaries” (APLS).